Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results…
Q1 2018 ObsEva SA Earnings Conference Call
ObsEva Annual General Meeting 2018
Wednesday, May 9, 2018 Location: Geneva Supporting Materials:
ObsEva Annual General Meeting 2018
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
Geneva, Switzerland and Boston, MA – May 8, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women
Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
ObsEva on page 17 of Understanding Fertility Special Report 2018
Special report in the Raconteur Article in ‘The Times’ Click here for publication link IVF ‘BREAKTHROUGH’ TREATMENT Pioneering use of…